STOCK TITAN

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and provide company updates.

Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live audio webcast with accompanying slides will be available on the company's investor relations website, with an archived version accessible approximately two hours after the event.

Loading...
Loading translation...
Argus Session date unavailable
-2.28% session move Open Argus
Details

News Market Reaction – KPTI

The recorded move for KPTI in the trading session of this news was -2.28%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

-- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET --

NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

(PRNewsfoto/Karyopharm Therapeutics Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-first-quarter-2025-financial-results-on-may-12-2025-302450543.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Karyopharm (KPTI) report Q1 2025 earnings?

Karyopharm will report its Q1 2025 earnings on Monday, May 12, 2025, at 4:30 p.m. ET.

How can I access Karyopharm's Q1 2025 earnings call?

You can access the call by dialing (800) 836-8184 (local) or (646) 357-8785 (international), or via webcast on the company's investor website.

Where can I find the webcast of KPTI's Q1 2025 earnings call?

The webcast will be available under 'Events & Presentations' in the Investor section at http://investors.karyopharm.com/events-presentations

What does Karyopharm Therapeutics (KPTI) do?

Karyopharm Therapeutics is a commercial-stage pharmaceutical company that develops novel cancer therapies.

Keep reading